Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
4D Molecular Therapeutics | FDMT | Nov 22, 2024 | 7.79 | -2.50 |
51Talk Online Education Group ADR | COE | Nov 22, 2024 | 14.92 | -2.55 |
5E Advanced Materials | FEAM | Nov 22, 2024 | 0.50 | +8.98 |
60 Degrees Pharmaceuticals | SXTP | Nov 22, 2024 | 0.90 | +2.97 |
7-10 Yr Trsy Bear 3X Direxion | TYO | Nov 22, 2024 | 14.43 | -0.28 |
7-10 Yr Trsy Bull 3X Direxion | TYD | Nov 22, 2024 | 24.46 | +0.12 |
7-10 Yr Trsy Ishares | IEF | Nov 22, 2024 | 93.60 | +0.06 |
89bio | ETNB | Nov 22, 2024 | 8.76 | +4.53 |
8x8 | EGHT | Nov 22, 2024 | 3.04 | +3.05 |
908 Devices | MASS | Nov 22, 2024 | 2.56 | -6.57 |
99 Acquisition Group | NNAGU | Nov 22, 2024 | 10.60 | 0.00 |
9F ADR | JFU | Nov 22, 2024 | 1.37 | +2.63 |
A SPAC II Acquisition | ASCB | Nov 22, 2024 | 11.19 | 0.00 |
A-Mark Precious Metals | AMRK | Nov 22, 2024 | 29.74 | -0.57 |
a.k.a Brands | AKA | Nov 22, 2024 | 21.18 | +4.54 |
A.O Smith | AOS | Nov 22, 2024 | 73.44 | +0.64 |
A10 Networks | ATEN | Nov 22, 2024 | 16.62 | +0.36 |
A2Z Cust2Mate Solutions | AZ | Nov 22, 2024 | 6.94 | +8.02 |
AA Mission Acquisition | AAM | Nov 22, 2024 | 10.06 | 0.00 |
AAA - A Rated Corporate Bond Ishares | QLTA | Nov 22, 2024 | 47.35 | +0.02 |
Aadi Bioscience | AADI | Nov 22, 2024 | 2.30 | +0.88 |
AAON | AAON | Nov 22, 2024 | 137.42 | +1.37 |
AAR | AIR | Nov 22, 2024 | 69.08 | +1.83 |
Abacus Life | ABL | Nov 22, 2024 | 7.55 | -13.32 |
Abbott Laboratories | ABT | Nov 22, 2024 | 117.76 | +0.43 |
AbbVie | ABBV | Nov 22, 2024 | 176.95 | +3.04 |
AbCellera Biologics | ABCL | Nov 22, 2024 | 2.76 | +1.47 |
Abeona Therapeutics | ABEO | Nov 22, 2024 | 5.98 | +3.28 |
Abercrombie & Fitch | ANF | Nov 22, 2024 | 151.99 | +7.36 |
Aberdeen Asia-Pacificome Fund | FAX | Nov 22, 2024 | 15.77 | +0.45 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.